Nature Communications (Nov 2020)

Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

  • Antonio Molinaro,
  • Pierre Bel Lassen,
  • Marcus Henricsson,
  • Hao Wu,
  • Solia Adriouch,
  • Eugeni Belda,
  • Rima Chakaroun,
  • Trine Nielsen,
  • Per-Olof Bergh,
  • Christine Rouault,
  • Sébastien André,
  • Florian Marquet,
  • Fabrizio Andreelli,
  • Joe-Elie Salem,
  • Karen Assmann,
  • Jean-Philippe Bastard,
  • Sofia Forslund,
  • Emmanuelle Le Chatelier,
  • Gwen Falony,
  • Nicolas Pons,
  • Edi Prifti,
  • Benoit Quinquis,
  • Hugo Roume,
  • Sara Vieira-Silva,
  • Tue H. Hansen,
  • Helle Krogh Pedersen,
  • Christian Lewinter,
  • Nadja B. Sønderskov,
  • The MetaCardis Consortium,
  • Lars Køber,
  • Henrik Vestergaard,
  • Torben Hansen,
  • Jean-Daniel Zucker,
  • Pilar Galan,
  • Marc-Emmanuel Dumas,
  • Jeroen Raes,
  • Jean-Michel Oppert,
  • Ivica Letunic,
  • Jens Nielsen,
  • Peer Bork,
  • S. Dusko Ehrlich,
  • Michael Stumvoll,
  • Oluf Pedersen,
  • Judith Aron-Wisnewsky,
  • Karine Clément,
  • Fredrik Bäckhed

DOI
https://doi.org/10.1038/s41467-020-19589-w
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 10

Abstract

Read online

Gut microbial metabolism of nutrients contributes to metabolic diseases, and the histidine metabolite imidazole propionate (ImP) is produced by type 2 diabetes (T2D) associated microbiome. Here the authors report that circulating ImP levels are increased in subjects with prediabetes or T2D in three European populations, and this increase associates with altered gut microbiota rather than dietary histidine.